Infection Events Synthetic Swarm for Tracking Independent Immunodeficiency Virus SIVmac 239 Molecularly Tagged Simian

Following mucosal human immunodeficiency virus type 1 transmission, systemic infection is established by one or only a few viral variants. Modeling single-variant, mucosal transmission in nonhuman primates using limiting-dose inoculations with a diverse simian immunodeficiency virus isolate stock may increase variability between animals since individual variants within the stock may have substantial functional differences. To decrease variability between animals while retaining the ability to enumerate transmitted/founder variants by sequence analysis, we modified the SIVmac239 clone to generate 10 unique clones that differ by two or three synonymous mutations (molecular tags). Transfectionand infection-derived virus stocks containing all 10 variants showed limited phenotypic differences in 9 of the 10 clones. Twenty-nine rhesus macaques were challenged intrarectally or intravenously with either a single dose or repeated, limiting doses of either stock. The proportion of each variant within each inoculum and in plasma from infected animals was determined by using a novel real-time single-genome amplification assay. Each animal was infected with one to five variants, the number correlating with the dose. Longitudinal sequence analysis revealed that the molecular tags are highly stable with no reversion to the parental sequence detected in >2 years of follow-up. Overall, the viral stocks are functional and mucosally transmissible and the number of variants is conveniently discernible by sequence analysis of a small amplicon. This approach should be useful for tracking individual infection events in preclinical vaccine evaluations, long-term viral reservoir establishment/clearance research, and transmission/early-event studies.

[1]  C. Fennessey,et al.  Using nonhuman primates to model HIV transmission , 2013, Current opinion in HIV and AIDS.

[2]  G. Learn,et al.  Heterogeneity in Neutralization Sensitivities of Viruses Comprising the Simian Immunodeficiency Virus SIVsmE660 Isolate and Vaccine Challenge Stock , 2013, Journal of Virology.

[3]  Christopher J. Miller,et al.  Comparative Characterization of Transfection- and Infection-Derived Simian Immunodeficiency Virus Challenge Stocks for In Vivo Nonhuman Primate Studies , 2013, Journal of Virology.

[4]  G. Learn,et al.  Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. , 2013, Virology.

[5]  D. Montefiori,et al.  Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIVmac251 at Challenge Exposure , 2013, Journal of Virology.

[6]  D. Watkins,et al.  A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. , 2012, Vaccine.

[7]  J. Shiver,et al.  Low-Dose Penile SIVmac251 Exposure of Rhesus Macaques Infected with Adenovirus Type 5 (Ad5) and Then Immunized with a Replication-Defective Ad5-Based SIV gag/pol/nef Vaccine Recapitulates the Results of the Phase IIb Step Trial of a Similar HIV-1 Vaccine , 2011, Journal of Virology.

[8]  J. Lifson,et al.  SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. , 2011, AIDS research and human retroviruses.

[9]  B. Keele,et al.  Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge , 2011, Mucosal Immunology.

[10]  Christopher J. Miller,et al.  TRIM5α Does Not Affect Simian Immunodeficiency Virus SIVmac251 Replication in Vaccinated or Unvaccinated Indian Rhesus Macaques following Intrarectal Challenge Exposure , 2011, Journal of Virology.

[11]  John P. Moore,et al.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody , 2011, Proceedings of the National Academy of Sciences.

[12]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[13]  M. Essex,et al.  Transmission of Single and Multiple Viral Variants in Primary HIV-1 Subtype C Infection , 2011, PloS one.

[14]  Alan S. Perelson,et al.  Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing , 2010, PloS one.

[15]  B. Haynes,et al.  Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys , 2010, Journal of Virology.

[16]  G. Shaw,et al.  A Limited Number of Simian Immunodeficiency Virus (SIV) env Variants Are Transmitted to Rhesus Macaques Vaginally Inoculated with SIVmac251 , 2010, Journal of Virology.

[17]  Alan S. Perelson,et al.  High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men , 2010, PLoS pathogens.

[18]  H. Chu,et al.  Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants , 2009, Journal of Virology.

[19]  A. Perelson,et al.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection , 2009, The Journal of experimental medicine.

[20]  Alan S. Perelson,et al.  Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1 , 2009, The Journal of experimental medicine.

[21]  D. Watkins,et al.  Vaccine-Induced Cellular Responses Control Simian Immunodeficiency Virus Replication after Heterologous Challenge , 2009, Journal of Virology.

[22]  Cynthia A. Derdeyn,et al.  Inflammatory Genital Infections Mitigate a Severe Genetic Bottleneck in Heterosexual Transmission of Subtype A and C HIV-1 , 2009, PLoS pathogens.

[23]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[24]  R. Gorelick,et al.  HIV-1 inactivation by 4-vinylpyridine is enhanced by dissociating Zn(2+) from nucleocapsid protein. , 2008, Virology.

[25]  B. Korber,et al.  Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing , 2008, Journal of Virology.

[26]  M. Carrington,et al.  Mamu-B*08-Positive Macaques Control Simian Immunodeficiency Virus Replication , 2007, Journal of Virology.

[27]  J. Lifson,et al.  Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS , 2005, Journal of medical primatology.

[28]  D. Robertson,et al.  Molecular Epidemiology of Simian Immunodeficiency Virus SIVsm in U.S. Primate Centers Unravels the Origin of SIVmac and SIVstm , 2005, Journal of Virology.

[29]  John W. Mellors,et al.  Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.

[30]  R. Desrosiers,et al.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS , 1991, Cell.

[31]  R. Desrosiers,et al.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. , 1990, AIDS research and human retroviruses.

[32]  R. Desrosiers,et al.  Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. , 1985, Science.

[33]  J. Lifson,et al.  Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. , 2000, Advances in pharmacology.